Want to see ROIV full AI Analyst Report?
ROIV Stock Chart & Stats
$29.83
-$0.41(-3.60%)
At close: 4:00 PM EST
$29.83
-$0.41(-3.60%)
Day’s Range― - ―
52-Week Range$10.90 - $37.00
Previous CloseN/A
Volume1.46M
Average Volume (3M)5.84M
Market Cap
$26.48B
Enterprise Value$21.13B
Total Cash (Recent Filing)$4.30B
Total Debt (Recent Filing)$107.44M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 17, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding719,270,400
10 Day Avg. Volume6,051,472
30 Day Avg. Volume5,836,917
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue2.56K
Enterprise Value/Gross Profit3.03K
Enterprise Value/Ebitda-80.87
Forecast
1Y Price Target
$36.72Price Target Upside23.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$75.84M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity & Low LeverageA large cash reserve and negligible debt provide durable optionality to fund clinical programs, commercial launches, and partnerships without near‑term financing pressure. The Moderna settlement further bolsters runway, reducing execution risk over the next 2–6 months while late‑stage programs read out.
High Gross Margin ProfileVery high gross margins indicate that once product revenues scale, Roivant can convert incremental sales into operating leverage. This structural margin strength supports path to profitability over time as SG&A and R&D are leveraged across a growing commercial portfolio.
Demonstrated Clinical Execution & EnrollmentConsistent, rapid enrollment and timely execution across several programs (1402, mosli, CLE, brepocitinib) reflect strong operational capability and investigator engagement. That structural execution reduces timeline uncertainty and increases probability of informative readouts and regulatory interactions.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow is a durable constraint: even with sizable cash, continued quarterly burn will deplete reserves unless offset by product revenue, milestone receipts, or asset monetizations. This elevates financing or dilution risk over the medium term.
Declining Revenue & Ongoing LossesMaterial operating losses and a marked revenue decline indicate the company has not yet reached commercial scale. Structural negative profitability limits reinvestment capacity and keeps returns on equity negative until sustainable product sales or recurring partner income emerge.
Clinical Interpretability & Regulatory RiskKey efficacy evidence rests on open‑label data and a potentially hard‑to‑separate randomized‑withdrawal endpoint. These design and interpretability risks are structural for regulatory review and commercial differentiation, increasing the chance that further trials or analyses will be required before approvals or broad uptake.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences Ltd.’s price range in the past 12 months?
Roivant Sciences Ltd. lowest stock price was $10.90 and its highest was $37.00 in the past 12 months.
What is Roivant Sciences Ltd.’s market cap?
Roivant Sciences Ltd.’s market cap is $26.48B.
When is Roivant Sciences Ltd.’s upcoming earnings report date?
Roivant Sciences Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Roivant Sciences Ltd.’s earnings last quarter?
Roivant Sciences Ltd. released its earnings results on May 20, 2026. The company reported $0.279 earnings per share for the quarter, beating the consensus estimate of -$0.289 by $0.568.
Is Roivant Sciences Ltd. overvalued?
According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued.
Does Roivant Sciences Ltd. pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
What is Roivant Sciences Ltd.’s EPS estimate?
Roivant Sciences Ltd.’s EPS estimate is -0.29.
How many shares outstanding does Roivant Sciences Ltd. have?
Roivant Sciences Ltd. has 719,270,400 shares outstanding.
What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?
Roivant Sciences Ltd. reported an EPS of $0.279 in its last earnings report, beating expectations of -$0.289. Following the earnings report the stock price went up 14.888%.
Which hedge fund is a major shareholder of Roivant Sciences Ltd.?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.72 (23.11% Upside)
$36.72 (23.11% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 10.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $217.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 24.8%
Last 30 Days ▲ 24.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
228.07%
12-Months-Change
Fundamentals
Return on Equity
-6.85%
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong clinical signals (notably the robust open-label 1402 RA responses and mosli hemodynamic activity), solid financial backing (cash of $4.3B and a $2.25B Moderna settlement), and rapid execution across trials and commercial prep. Key risks were acknowledged: interpretability limitations from open-label data, potential difficulty meeting the randomized withdrawal primary endpoint for 1402, some program failures (bitokamab), pending biomarker analyses, and competitive/ regulatory hurdles in indications like CLE and PH-ILD. On balance, the pipeline momentum, cash position, and high-impact data presented outweigh the noted challenges, though important uncertainties remain that will require follow-up data and regulatory feedback.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$36.72
▲(23.11% Upside)
Technical Analysis
Ownership Overview
19.60% Insiders
17.00% Mutual Funds
1.21% Other Institutional Investors
47.68% Public Companies and
Individual Investors